For Immediate Release - November 17, 2000
ULSTER COUNTY CONSUMERS COULD SAVE OVER $43 MILLION ON
PRESCRIPTION DRUGS UNDER NEW SCHUMER-MCCAIN BILL
Generic alternatives could save local residents nearly $575
annually on Claritin, according to Schumer survey
Schumer-McCain bill will encourage competition in the
pharmaceutical marketplace by leveling playing field for generic drug
makers Underscoring the need for cheaper prescription drugs, US Senator
Charles E. Schumer today released data showing that Ulster County residents
would see significant savings on their prescription drug expenses if low cost
generic alternatives were available under legislation co-authored by Schumer and
Senator John McCain (R-AZ). The Schumer-McCain bill could help save Ulster
County consumers over $43 million on their prescription drug costs over the next
ten years if passed by Congress, according to Schumer estimates based on a study
by the Prime Institute at the University of Minnesota.
Schumer surveyed local pharmacies to determine the costs of five
widely prescribed drugs and found that Ulster County residents would see annual
savings of hundreds of dollars on a number of prescriptions if generic
alternatives are available when the original patents for the brand name drugs
are due to expire. But under current law the pharmaceutical industry
regularly seizes upon loopholes to block generic drugs from entering the market.
"In 1984, Congress passed a far reaching pro-consumer law which
created a blueprint to allow less expensive generic drugs to enter the
market. In recent years, as the stakes and drug company profits have grown
larger, the lawyers have picked this law clean," said Schumer. "If this
pro-consumer law isn't dead, it's dying."
To restore the original purpose of the 1984 generic drug law, also
known as Hatch-Waxman, Schumer and McCain last month introduced the Greater
Access to Affordable Pharmaceuticals Act (GAAP) to allow generic drug
companies to enter the market promptly after brand name company patents
expire. The bill seeks to speed the approval of generic drugs by the Food
and Drug Administration by eliminating legal hurdles and loopholes that have
nothing to do with the medication's effectiveness.
"The original law allowed brand name companies to have a set
amount of time of market exclusivity rights before a bio-equivalent generic drug
could compete on the market. But when the clock runs out, the drug company
tries to keep the generic from entering the marketplace over some frivolous
reason like the shape of the pill or the color of the bottle," said
Schumer. "It would be laughable were it not costing individual consumers
hundreds of dollars each year."
Under the Schumer-McCain legislation:
• The number of patents that a generic drug company must address for FDA approval would be limited to two categories – how the drug works and how it is taken. Other frivolous patent challenges on such items as the color and shape of pills and bottles would be barred.
• It blocks brand name companies from paying generic manufacturers to keep their product off the market. Recently, Abbott Laboratories admitted to paying Geneva Pharmaceuticals $4.5 million a month to keep its generic equivalent of the hypertension and prostate cancer drug Hytrin off the market.
•
It
expands the FDA's jurisdiction to allow for approval of generic versions of
inhalers and topical treatments like skin ointments. Currently, only
generic oral and intravenous medications can be readily approved by the FDA.
According to Schumer estimates based on Prime Institute findings, if generic
drugs are able to come to market as soon as brand-name patents expire, US
consumers could save $71 billion on prescription drugs over the next 10
years. The Prime Institute estimates that by the third year a generic
alternative is on the market, consumers save, on average, 60% when they choose
the generic over the name brand. In Ulster County, those savings could
mean $43.6 million for local residents over the next ten years.
In his survey of local drug costs, Schumer found that an area
resident using Prilosec, a widely-used ulcer medication, could save more than
$933 a year if a generic were available – $622 for the generic versus $1,555 for
the branded version. Instead of spending $1,506 annually on a prescription
of Zocor, a popular cholesterol medication, Ulster County residents could save
more than $904 by buying a generic version of the drug for only $602 per year.
A person taking Norvasc, a commonly prescribed drug for heart
disease, normally pays about $44.99 for a month's supply at the CVS in
Kingston. If a generic were available, that person would have the option
of paying an estimated $18.00 a month and would save more than $324
annually. Similarly, a person filling a prescription of Claritin pays
$81.45 a month at Matthews Pharmacy in Ellenville, but would have to pay only
about $32.58 for a generic version, saving more than $586 annually. Finally, a
person taking Zocor for cholesterol who currently pays $139.30 a month at Valley
Pharmacy in Pine Bush would only pay $55.72 for a generic alternative, saving
almost $1,003 annually.
Schumer said that an added benefit to his bipartisan bill is that
it will not get caught in the partisan battles that have doomed other efforts to
make prescription drugs more affordable.
"Over the years, every attempt to make prescription drugs more
affordable for working families has broken down over partisan or ideological
lines," said Schumer. "We are accomplishing these huge savings not by redrawing
ideological battle lines, but by restoring the intent of our patent laws."
The Schumer-McCain bill has been endorsed by the Health Insurance
Association of America (HIAA), the Consumer Federation of America (CFA), Blue
Cross/Blue Shield, the Academy of Managed Care Pharmacy, the Consumers Union,
the National Consumer League and the Alliance of Community Health Plans.
"It isn't often that these groups come together to endorse a
bill. I think it means that John McCain and I are on to something pretty
special," said Schumer.
# # #